|Videos|August 24, 2022
Patient Eligibility and Logistical and Safety Considerations for Tebentafusp Treatment in mUM
Author(s)Sunandana Chandra, MD, MS
An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
Simple Ways for Patients With Cancer to Start Exercising
2
Anemia Management in Myelofibrosis: Survival and Quality of Life
3
Finding Credible Voices in the Lynch Syndrome Community
4
How Does FDA-Approved Blenrep Treat Multiple Myeloma?
5
